RESprotect Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Out of Business

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Out of Business

RESprotect General Information

Description

Developer of cancer drugs intended for the prevention and treatment of chemotherapeutic drug resistance and radiation therapy resistance. The company's small molecule drugs contain products such as Hsp27 and RP101 which are given orally to cancer patients in combination with standard-of-care chemotherapy, enabling pancreatic cancer patients to kill tumor cells.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Fiedlerstr. 34
  • 01259 Dresden
  • Germany
+49 0351
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Vertical(s)
Corporate Office
  • Fiedlerstr. 34
  • 01259 Dresden
  • Germany
+49 0351

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RESprotect Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Aug-2023 Completed Out of Business
3. Secondary Transaction - Private 01-Sep-2021 Completed Generating Revenue
2. Secondary Transaction - Private 15-Apr-2009 $1M $6.33M Completed Startup
1. Early Stage VC 30-Aug-2000 $6.33M $6.33M Completed Startup
To view RESprotect’s complete valuation and funding history, request access »

RESprotect Patents

RESprotect Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
DE-102008035299-A1 Conjugate, particularly bromovinyl-deoxyuridine for manufacture medicament for inhibiting or suppressing metastasis including distant metastases in cytostatic treatment, includes heat shock protein and nucleoside Inactive 29-Jul-2008
DE-102008030091-A1 Uracil derivatives and their use Active 25-Jun-2008
DE-102008030091-B4 Uracil derivatives and their use Inactive 25-Jun-2008
EP-2303848-A2 Uracil derivatives and use thereof Inactive 25-Jun-2008
US-20110166096-A1 Uracil derivatives and use thereof Active 25-Jun-2008 C07D239/54
To view RESprotect’s complete patent history, request access »

RESprotect Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

RESprotect FAQs

  • When was RESprotect founded?

    RESprotect was founded in 2000.

  • Where is RESprotect headquartered?

    RESprotect is headquartered in Dresden, Germany.

  • What is the size of RESprotect?

    RESprotect has 5 total employees.

  • What industry is RESprotect in?

    RESprotect’s primary industry is Drug Discovery.

  • Is RESprotect a private or public company?

    RESprotect is a Private company.

  • What is RESprotect’s current revenue?

    The current revenue for RESprotect is .

  • How much funding has RESprotect raised over time?

    RESprotect has raised $6.33M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process